Alexander Hoffmann
Principal @ M Ventures
Amsterdam, The Netherlands
Alexander Hoffmann is a Series A investor at M Ventures in Amsterdam focused on Food and Beverage and Wearables. Alexander Hoffmann joined the New Businesses team as Principal in October 2016. Previously, Alexander was the Head of Digitization Africa, leading the Digital Strategy for Africa at Merck. Based out of Nairobi, Kenya, he was instrumental for the launch and management of several digital health solutions supporting the existing businesses of Merckacross the continent. He was also the main driver of the Merck Africa Accelerator program, looking after digital health startups in this region. Prior to that, Alexander has held various positions at several internet startups, ranging from Skrill and SumUp (online and mobile payments) to consumer-focused online businesses at Rocket Internet. Alexander holds a Master’s degree in Marketing from Kingston Business School, UK. Alexander is based in Amsterdam.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 63%
Last updated:
For AI agents: llms.txt
Industries Alexander Hoffmann invests in
Stages Alexander Hoffmann invests in
Countries Alexander Hoffmann invests in
Investment Focus
Industry
- Food and Beverage 3 (38%)
- Wearables 2 (25%)
- Biotechnology 2 (25%)
- Food Processing 2 (25%)
- Alternative Protein 2 (25%)
Stage
- Series A 5 (63%)
- Pre-Seed 1 (13%)
- Series B 1 (13%)
- Series C 1 (13%)
Country
- United States 2 (25%)
- The Netherlands 2 (25%)
- Spain 1 (13%)
- Germany 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Biolinq
|
Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $100M / Series C / Mar 19, 2025 | |
NOVAMEAT
|
NOVAMEAT develops cutting-edge technological solutions to feed the planet’s growing population with plant-based foods in order to overcome the challenges of today’s unsustainable and inefficient animal agriculture industry and create a healthy, efficient, humane and sustainable food supply system.NOVAMEAT's proprietary technologies allowproducing plant-based meat substitutes with the same texture, appearance, taste and nutritional properties as a variety of animal meat products, including beef steaks.NOVAMEAT was recently featured on Bloomberg, Forbes, Business Insider, CBS, Techcrunch, Seeker, Mashable, Euronews, Newsweek, Mirror, El Pais, and CNN. | $19.3M / Series A / Sep 12, 2024 | |
Farmless
|
A farmless fermentation platform has the potential to create an entirely new food repertoire, producing proteins, carbohydrates, beneficial fats, vitamins, and minerals from the ground up," explained Oner. "We are creating a new interface between food and electricity by domesticating microbes chosen for their food properties and abilityto grow on renewable energy-based feedstocks. | $1.3M / Pre-Seed / May 10, 2023 | |
Mosa Meat
|
Mosa Meat produces slaughter-free hamburgers. The burger is harvested from cow cells, rather than raising and slaughtering a whole animal. By growing meat naturally from cells, Mosa Meat strives to accelerate the transition to a truly sustainable global food system. | $55M / Series B / Sep 25, 2020 | |
Micropsi Industries
|
Micropsi Industries is building cognitive machines: Theyr’re providing high-end machine learning solutions for robotics and process control.micropsi industries MIRAI is a robot control system designed for complex assembly tasks. MIRAI-controlled robots perform movements that react to minute changes in the environment, as perceived by the robotwith cameras or force sensors. MIRAI skills aren't programmed, but trained - through demonstration, correction, and repetition. This allows users to create skills without writing a single line of code or modelling the problem.The company was founded in 2014 by a group of experienced entrepreneurs, software engineers and scientists, most of them with cognitive science or machine learning backgrounds. micropsi industries is backed by Vito Ventures, coparion, and a group of experienced business angels from Munich and Berlin. | Series A / Jun 18, 2020 | |
Neurable
|
Neurable is a neurotechnology company specializing in developing AI-powered tools for brain signal translation and brain-computer interface technology. Utilizing patented signal processing, developed through research across labs and institutions, and advanced by a scientific and expert product team, its platform enables high-performancebrain-computer interface in everyday devices. | $6M / Series A / Dec 18, 2019 | |
|
Mosa Meat
|
Mosa Meat produces slaughter-free hamburgers. The burger is harvested from cow cells, rather than raising and slaughtering a whole animal. By growing meat naturally from cells, Mosa Meat strives to accelerate the transition to a truly sustainable global food system. | $8.2M / Series A / Jul 17, 2018 | |
|
Biolinq
|
Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $10M / Series A / Nov 27, 2017 |
Co-Investors
About M Ventures
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
M Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Christian Patze
Associate, Performance Materials
|
|||
Noga Yerushalmi
Head of Israel Bio-incubator
|
|||
Sarah Luppino
Associate
|
|||
|
Alexander Hoffmann
Principal
|
|||
Alicia Iruzun Lafitte
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alexander Hoffmann invest in?
Alexander Hoffmann invests primarily in Food and Beverage, Wearables and Biotechnology startups, most often at Series A and Pre-Seed stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Alexander Hoffmann last invest?
The most recent investment recorded for Alexander Hoffmann closed in Mar 2025. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
